ID: ALA395347

Max Phase: Preclinical

Molecular Formula: C16H12BrF2NO3S

Molecular Weight: 416.24

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)COc1cc(F)ccc1C(=S)NCc1ccc(Br)cc1F

Standard InChI:  InChI=1S/C16H12BrF2NO3S/c17-10-2-1-9(13(19)5-10)7-20-16(24)12-4-3-11(18)6-14(12)23-8-15(21)22/h1-6H,7-8H2,(H,20,24)(H,21,22)

Standard InChI Key:  JCZUIWYXULSXSW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 416.24

Molecular Weight (Monoisotopic): 414.9689

AlogP: 3.66

#Rotatable Bonds: 6

Polar Surface Area: 58.56

Molecular Species: ACID

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.30

CX Basic pKa:

CX LogP: 4.04

CX LogD: 0.61

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.70

Np Likeness Score: -1.57

References

1. Ferrari AM, Degliesposti G, Sgobba M, Rastelli G..  (2007)  Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.,  15  (24): [PMID:17870536] [10.1016/j.bmc.2007.08.019]

2. Maccari R, Ottanà R..  (2015)  Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.,  58  (5): [PMID:25375908] [10.1021/jm500907a]

3. Kousaxidis A, Petrou A, Lavrentaki V, Fesatidou M, Nicolaou I, Geronikaki A..  (2020)  Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.,  207  [PMID:32871344] [10.1016/j.ejmech.2020.112742]

Source

Source(1):

• Scientific Literature